BioGenerator Ventures
BioGenerator Ventures is the St. Louis-based investment arm of BioSTL that creates, builds, and invests catalytic early-stage capital in life sciences startups spanning human health (therapeutics, diagnostics, medical devices) and agriculture technology, bundling investment with the BioGenerator Labs company-building engine of coaching, lab facilities, and grant support.
- Company typePrivate
- Founded2004
- HeadquartersSt Louis, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What BioGenerator Ventures does
BioGenerator Ventures is the venture creation and investment arm of BioSTL, a St. Louis-based nonprofit bioscience ecosystem organization. Founded in 2003/2004, the firm creates, builds, and invests in early-stage life sciences companies solving problems in human health and agriculture, operating from its 4340 Duncan Avenue headquarters with facilities co-located at the Cortex Innovation Community and the 39N agtech district. BioGenerator typically serves as the first professional capital into portfolio companies and syndicates with a global network of 250+ venture capital, private equity, and strategic investors including Novo Holdings, NEA, ARCH Venture Partners, GV, Leaps by Bayer, AbbVie Ventures, and Roche Venture Fund.
The firm's core offering combines catalytic investment capital with the proprietary BioGenerator Labs engine — a suite of company-building resources including coaching from Executives in Residence, SBIR/STTR non-dilutive grant training and acquisition support, shared capital equipment, innovative wet laboratory space at Cortex and 39N, talent recruitment via a VC Fellow program, and investor relations support. BioGenerator has cumulatively invested more than $50 million across 130+ portfolio companies (Geneoscopy, Benson Hill, MediBeacon, Wugen, SentiAR, CoverCress, Plastomics, Canopy Biosciences, Confluence Life Sciences, DiSARM, Solis Agrosciences), with portfolio companies attracting roughly $2.8–3 billion in follow-on capital — approximately a 60X leverage on direct investment. Demonstrated exits include Galera Therapeutics' 2019 $60M NASDAQ IPO, Canopy Biosciences' 2020 acquisition by Bruker, Benson Hill's 2021 $2B SPAC merger on the NYSE, CoverCress's 2022 acquisition of a 65% controlling interest by Bayer, Confluence Life Sciences' acquisition by Aclaris Therapeutics, DiSARM's acquisition by Eli Lilly for up to $1.2 billion, and CareSignal's acquisition by Lightbeam Health Solutions.
BioGenerator generates revenue through returns on invested capital (exit proceeds, equity appreciation, follow-on participation) and management economics on its evergreen fund structure, which includes BioGenerator Fund I (closed 2017) and two new venture funds totaling $40 million announced in 2025 targeting biotech tools, agtech, and digital health/AI. The firm is led by Senior Managing Director James McCarter (appointed October 2024) and Senior Managing Director Charlie Bolten, who succeeded retiring President Eric Gulve in December 2022. BioGenerator does not sell commercial products; its customers are portfolio companies and the broader St. Louis bioscience ecosystem of academic researchers and entrepreneurs, primarily sourced from Washington University and the Danforth Plant Science Center.
BioGenerator Ventures firmographics
Firmographics- Name
- BioGenerator Ventures
- Legal name
- BioGenerator
- Website
- https://biogeneratorventures.com
- Company type
- Private
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BioGenerator Ventures is the St. Louis-based investment arm of BioSTL that creates, builds, and invests catalytic early-stage capital in life sciences startups spanning human health (therapeutics, diagnostics, medical devices) and agriculture technology, bundling investment with the BioGenerator Labs company-building engine of coaching, lab facilities, and grant support.
- Ownership category
- akta.pro rank
BioGenerator Ventures industry classification
Industry- Product category
- Venture Capital and Life Sciences Company Building
- NAICS
- Other Financial Vehicles (52599), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Investment Advice (6282), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Accelerators & Incubators (Investor-Operated) (FSANAAAM)
- akta.pro secondary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
Keywords
Where BioGenerator Ventures is headquartered
LocationHeadquarters
- HQ city
- St Louis
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
BioGenerator Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D
Revenue model
- Investment Returns: BioGenerator Ventures invests capital into early-stage life sciences companies and generates returns through successful exits, follow-on investments, and portfolio company growth. The firm has achieved multiple successful exits including CoverCress (acquired by Bayer), Canopy Biosciences (acquired by Bruker), Confluence Life Sciences (acquired by Aclaris), DiSARM (acquired by Lilly), and others.
- Portfolio Company Success: Revenue generated through equity appreciation in portfolio companies, IPO exits, and acquisitions. Companies have raised over $2.8B in follow-on capital.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels7 records
BioGenerator Ventures product offering
Product offeringCore offering
BioGenerator Ventures is a venture capital and company-creation firm that makes catalytic early-stage investments in life sciences companies in human health and agriculture. It pairs capital with the BioGenerator Labs engine, providing coaching from Executives in Residence, SBIR/STTR grant training, non-dilutive funding support, shared wet laboratory space at the Cortex Innovation Community and 39N agtech district, talent access through its VC Fellow program, and investor relations support to portfolio companies.
Product overview
BioGenerator Ventures is not a product company but rather a venture capital and company-building organization. It operates as the investment arm of BioSTL, creating and building life sciences companies in human health and agriculture. Its core offering is catalytic investment capital combined with BioGenerator Labs—a suite of company-building resources including coaching from Executives in Residence, SBIR/STTR grant training, shared laboratory facilities at Cortex Innovation Community and 39N agtech district, and talent access. BioGenerator does not develop or sell its own commercial products; rather, it builds portfolio companies and supports their development through pre-company grants, early financing, and ongoing operational support. The named services include investment capital deployment, non-dilutive grant acquisition support, physical lab facilities, coaching and mentorship, and investor relations assistance.
Differentiator
Problem solved
Functional benefit
Products and services
- BioGenerator Ventures (Catalytic Investment Capital) Early-stage venture capital investments into life sciences startups focused on human health and agriculture. BioGenerator often leads first financing rounds and continues to invest across multiple rounds for companies achieving milestones, and syndicates with top global VC, PE, and strategic investors.
- BioGenerator Labs (Company-Building Engine) Integrated suite of company-building resources offered alongside BioGenerator Ventures capital, combining technology, talent, proof-of-concept grants, coaching, grant training, and laboratory space to accelerate the development of portfolio companies.
- SBIR/STTR Grant Winning Program
Quantifiable outcome
- >$60X leverage of BioGenerator invested capital through follow-on funding
- +2 more outcomes
Companies that use BioGenerator Ventures
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles3 records
BioGenerator Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
BioGenerator Ventures partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- EvogenecoreCollaboration agreement between Plastomics and Evogene's Ag-Seed division targeting novel insect control traits for soybean using Plastomics' chloroplast transformation technology and Evogene's candidate genes.
- Washington University in St. LouiscoreKey academic partner for technology licensing; multiple portfolio companies (Wugen, Disarm, SentiAR, others) licensed technology from Washington University.
- Donald Danforth Plant Science CentercorePartner providing greenhouse space and specialized capabilities for agricultural technology companies at the 39N innovation district.
- Cortex Innovation CommunitycoreSt. Louis innovation district housing BioGenerator Labs facilities for life sciences companies.
Scale indicators8 records
Recent moves8 records
Expansion highlights5 records
BioGenerator Ventures competitors and assessment
Company assessmentDirect peers
- ARCH Venture Partners: Chicago-based early-stage biotech venture capital firm that creates and funds life sciences companies. Highly comparable to BioGenerator given shared focus on company creation, Midwest roots, and co-investment history (ARCH has invested in BioGenerator portfolio companies).
- Atlas Venture: Boston-based early-stage biotech venture capital firm that builds and funds life sciences startups from inception. Directly comparable business model — early-stage creation, syndication with larger VCs, focus on human health therapeutics and platforms.
- Flagship Pioneering: Cambridge-based firm that originates and builds biotech companies through a proprietary innovation engine. The closest analog to BioGenerator's 'company-creation plus capital' model, though at significantly larger scale and with more resources.
- 5AM Ventures: Early-stage life sciences venture capital firm focused on creating and funding biotech startups. Comparable in stage focus (seed/Series A), therapeutic breadth, and reliance on syndication with later-stage VCs.
- Frazier Life Sciences: Healthcare-dedicated venture capital firm investing across therapeutics, medical devices, and diagnostics. Comparable in stage and sector concentration, with similar syndication patterns across the life sciences VC ecosystem.
- Versant Ventures: Healthcare-focused venture capital firm with a dedicated company-creation practice (e.g., Inception Sciences). Closely mirrors BioGenerator's combination of catalytic capital and operational company-building support.
Regional players
- RiverVest Venture Partners: St. Louis-based healthcare-focused venture capital firm with deep ties to BioGenerator's portfolio (co-investor in multiple deals). Comparable in healthcare focus and Midwest regional concentration, though without the lab/incubator infrastructure of BioGenerator Labs.
Broad incumbents
- OrbiMed Advisors: Large, established healthcare-dedicated investment firm with funds across venture, growth, and public equity. Comparable sector focus but significantly broader in stage and capital base, often co-investing alongside BioGenerator in later rounds.
- Alexandria Venture Investments: Strategic venture capital arm of Alexandria Real Estate Equities focused on life sciences. Comparable in life sciences focus and role as a long-term capital partner to early-stage biotech, with co-investment history alongside BioGenerator in portfolio companies.
Emerging players
- IndieBio: Investor-operated biotech accelerator providing capital, lab space, and mentorship to early-stage life sciences startups. Direct analog to BioGenerator Labs' company-building engine, though IndieBio focuses more broadly on synthetic biology and operates a shorter program structure.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
BioGenerator Ventures social profiles
Digital presenceBioGenerator Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioGenerator Ventures leadership team
Management profileNumber of profiles
Profiles3 records
BioGenerator Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioGenerator Ventures M&A and investment
M&A and investmentM&A
Investments10 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioGenerator Ventures
What does BioGenerator Ventures do?
BioGenerator Ventures is a venture capital and company-creation firm that makes catalytic early-stage investments in life sciences companies in human health and agriculture. It pairs capital with the BioGenerator Labs engine, providing coaching from Executives in Residence, SBIR/STTR grant training, non-dilutive funding support, shared wet laboratory space at the Cortex Innovation Community and 39N agtech district, talent access through its VC Fellow program, and investor relations support to portfolio companies.
Is BioGenerator Ventures a public or private company?
BioGenerator Ventures is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was BioGenerator Ventures founded?
BioGenerator Ventures was founded in 2004. It employs 11 to 50 people.
Where is BioGenerator Ventures based?
BioGenerator Ventures is headquartered in St Louis, United States, in the North America region.
How does BioGenerator Ventures make money?
Two revenue lines are on record. Investment Returns are the primary driver. The others are portfolio Company Success.
Who are BioGenerator Ventures's main competitors?
Direct peers on record are ARCH Venture Partners, Atlas Venture, Flagship Pioneering, 5AM Ventures, Frazier Life Sciences and Versant Ventures. RiverVest Venture Partners is listed as a regional player. Broad incumbents are OrbiMed Advisors and Alexandria Venture Investments. IndieBio is listed as an emerging player.
Does BioGenerator Ventures have an API?
No public API is recorded for BioGenerator Ventures.
What industry is BioGenerator Ventures in?
BioGenerator Ventures's product category is Venture Capital and Life Sciences Company Building. Its primary akta.pro industry code is FSANAAAM, Accelerators & Incubators (Investor-Operated), with a secondary code of FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 52599 and its SIC code is 6282.